We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01078961
Recruitment Status : Completed
First Posted : March 2, 2010
Last Update Posted : June 8, 2016
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Ryan Sullivan, M.D., Massachusetts General Hospital